DiaMedica Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Note 11 - Net Loss Per Share (Tables)

Note 11 - Net Loss Per Share (Tables)

9 Months Ended

Sep. 30, 2023

Notes Tables

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

		Three Months Ended September 30,								Nine Months Ended September 30,
		2023				2022				2023				2022
Net loss		$	(4,471	)		$	(3,059	)		$	(14,220	)		$	(9,925	)
Weighted average shares outstanding—basic and diluted			37,949,422				26,443,067				30,751,329				26,443,067
Basic and diluted net loss per share		$	(0.12	)		$	(0.12	)		$	(0.46	)		$	(0.38	)

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

		Three Months Ended September 30,								Nine Months Ended September 30,
		2023				2022				2023				2022
Employee and non-employee stock options			3,698,513				2,775,998				3,698,513				2,775,998
Common shares issuable under common share purchase warrants			205,000				265,000				205,000				265,000
Common shares issuable under deferred stock units			213,905				134,402				213,905				134,402
Common shares issuable upon vesting of restricted stock units			4,289				—				4,289				—